NCT06977451View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

nL-CHCHD-001

Personalized Antisense Oligonucleotide

Trial Locations (1)

10032

Columbia University, Irving Medical Center, New York

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

n-Lorem Foundation

OTHER

NCT06977451 - Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS | Biotech Hunter | Biotech Hunter